0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Integrin alpha V beta 5

Integrin alpha V beta 5

Brief Information

Name:Integrin alpha-V/beta-5
Target Synonym:Receptors, Vitronectin
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

Part of Bioactivity data

IT5-H52W5-ELISA
Human ITGAV&ITGB5 Heterodimer Protein, His Tag&Tag FreeHuman ITGAV&ITGB5 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT5-H52W5) ELISA bioactivity

Immobilized Vitronectin at 2 μg/mL (100 μL/well) can bind Human ITGAV&ITGB5 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT5-H52W5) with a linear range of 2-20 ng/mL (QC tested).

IT5-H82Wa-ELISA
Biotinylated Human ITGAV&ITGB5 Heterodimer Protein, His,Avitag&Tag FreeBiotinylated Human ITGAV&ITGB5 Heterodimer Protein, His,Avitag&Tag Free (Cat. No. IT5-H82Wa) ELISA bioactivity

Immobilized Human Vitronectin at 5 μg/mL (100 μL/well) can bind Biotinylated Human ITGAV&ITGB5 Heterodimer Protein, His,Avitag&Tag Free (Cat. No. IT5-H82Wa) with a linear range of 0.01-0.156 μg/mL (QC tested).

Synonym Name

Integrin alpha V beta 5,ITGAVB5,ITGAV&ITGB5,ITGAV&B5

Background

Integrin alpha V beta 5 (ITGAV & ITGB5 or ITGAVB5) is expressed on a wide variety of cell types including keratinocytes, fibroblasts, adhesive monocytes, embryonic stem cells, and select endothelium and epithelium. ITGAV & ITGB5 binds ligands containing an RGD motif, notably vitronectin. Growth factors that increase PKC activity, such as VEGF or TGF alpha, promote ITGAVB5-mediated angiogenesis while alpha V beta 3, which may be expressed in the same cell, responds to FGF-basic and TNF alpha. An inhibitor of both down regulates tumor angiogenesis. During lung inflammation, up regulation of ITGAVB5 on myofibroblasts or infiltrating lymphocytes may contribute to fibrosis by freeing TGF beta from latency.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Risuteganib ALG-1001 Phase 2 Clinical Allegro Ophthalmics Retinal Diseases; Diabetic macular oedema; Diabetic Retinopathy; Macular Degeneration Details

This web search service is supported by Google Inc.

totop